Brought to you by 
Orphan drug developer Retrophin completes $25mm PIPE
26 Aug 2013
Executive Summary
First-time and returning institutional backers participated in a $25mm PIPE for Retrophin Inc. (rare pediatric disease therapeutics for neurological, renal, and muscular conditions). Investors bought 5.6mm shares for $4.50 (a 12% discount) and received five-year warrants to purchase 2.8mm shares at $6.00. The placement agents were Stifel Nicolaus & Co. and Roth Capital Partners. The company concurrently disclosed that it was negotiating an exclusive US license to a large pharmaco’s IP to develop a product for autism and schizophrenia. Retrophin will use the new funds to attempt to put this agreement in place.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com